Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Regulus Therapeutics Q2 EPS $(0.08), Inline

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 65.22 percent increase over losses of $(0.23) per share from the same period last
byBenzinga Newsdesk
August 10, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 65.22 percent increase over losses of $(0.23) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts